Sounds good mopar glad your gloomy outlook is starting to turn around. As I've maintained since the FDA's 2 key Rexista decisions last May ie: The fast track designation and skipping phase III as long as Bioequivalence could be proven...that logic strongly suggests that from that timeframe through to now...any and ALL potential Rexista partners will have been quietly negotiating behind the scenes with IPCI giving IPCI mgmt. a plethora of offers to consider.
Especially with IPCI's PODRAS technology platform being implemented into Rexista II directly on the heels of Rexista I approval right!
Soooooooooooo it's definitely going to get real interesting here over these 2 to 3 months as I'm adamant that prior to IPCI submitting their Rexista NDA to the FDA possibly as early as June...there's no chance in Hades that a very lucrative partnership announcement on Rexista hasn't already been announced well in advance of that coming FDA submission. And my main reason for drawing that logical conclusion is the simple fact that the big boy biotech firms IPCI's mgmt. is most likely in negotiations with behind the scenes aren't stupid enough to allow IPCI to continue going through all stages to FDA approval without selecting 1 of their many suitors in advance of IPCI mgmt. making Rexista far more lucrative by allowing IPCI to continue advancing through the FDA's stages to Rexista approval ok!
In fact I also believe that all of IPCI's Rexista suitors will want to partner on both Rexista versions...Rexista I and Rexista II incorporating PODRAS...so if I'm right and the potential Rexista partner is in fact negotiating for both Rexista versions...strap yourself in because that's going to be 1 VERY LUCRATIVE partnership announcement if/when it arrives glty!
News 
Market Data 
Discover 
